Latest by Myles Helfand
Prevalence of non-AIDS comorbidities prior to HIV diagnosis; wealth and HIV treatment access amidst universal health care; the uncertain benefits of food supplementation; the results of universal hepatitis C treatment access.
Substance use rates among people with HIV; the continuing risk of PML; tenofovir gel efficacy and menopause; the cumulative cost of the global fight against HIV.
The effect of vitamin D levels on CD4 count during HIV treatment; helping black men who have sex with men utilize PrEP; HIV and aortic stiffness; Legionnaires’ disease severity among people with HIV.
Tobacco use and HIV discrimination; enhancing viral suppression after prison with naltrexone; asymptomatic myocardial impairment during acute HIV infection; undetectability and yellow fever vaccine efficacy.
HIV in plasma vs. rectal mucosa; engagement in care while on PrEP; depression and outcomes among women with HIV; dolutegravir resistance in the wake of monotherapy.
Reductions in erectile function among men who have sex with men; Australia, San Francisco, and 90-90-90 “fast track” targets; hepatitis C infection and HIV risk; safety of the live herpes zoster vaccine.
Stroke risk among underrepresented populations; the realism of UNAIDS 90-90-90 goals; HIV persistence and inflammation amidst long-term suppression; HDL cholesterol as a predictor of immune recovery.
How West Virginia is responding; a text-message based continuum-of-care intervention; PrEP and risk compensation; a link between inflammation, frailty, and cytomegalovirus infection.
Primary care + HIV care = improved health care engagement; the efficacy of different HIV testing and treatment interventions; abdominal fat and hypertension rates; the ethics of HIV phylogenetics.
Whether a local HIV outbreak in Tijuana, Mexico, may be related to police activity; PrEP and stigma in hookup apps; HIV, aging, and the immune system; cannabis as a systemic anti-inflammatory.